79 related articles for article (PubMed ID: 11149677)
1. MR imaging in the evaluation of hepatic metastases.
Imam K; Bluemke DA
Magn Reson Imaging Clin N Am; 2000 Nov; 8(4):741-56. PubMed ID: 11149677
[TBL] [Abstract][Full Text] [Related]
2. Whole-body MR imaging versus sequential multimodal diagnostic algorithm for staging patients with rectal cancer: cost analysis.
Huppertz A; Schmidt M; Wagner M; Puettcher O; Asbach P; Strassburg J; Stöckmann F; Schöffski O; Maurer MH
Rofo; 2010 Sep; 182(9):793-802. PubMed ID: 20517819
[TBL] [Abstract][Full Text] [Related]
3. Diagnostic accuracy of CE-CT, MRI and FDG PET/CT for detecting colorectal cancer liver metastases in patients considered eligible for hepatic resection and/or local ablation.
Sivesgaard K; Larsen LP; Sørensen M; Kramer S; Schlander S; Amanavicius N; Bharadwaz A; Tønner Nielsen D; Viborg Mortensen F; Morre Pedersen E
Eur Radiol; 2018 Nov; 28(11):4735-4747. PubMed ID: 29736846
[TBL] [Abstract][Full Text] [Related]
4. Liver metastases: The role of magnetic resonance imaging.
Maino C; Vernuccio F; Cannella R; Cortese F; Franco PN; Gaetani C; Giannini V; Inchingolo R; Ippolito D; Defeudis A; Pilato G; Tore D; Faletti R; Gatti M
World J Gastroenterol; 2023 Sep; 29(36):5180-5197. PubMed ID: 37901445
[TBL] [Abstract][Full Text] [Related]
5. Focal Lesions of the Liver and Radiomics: What Do We Know?
Anichini M; Galluzzo A; Danti G; Grazzini G; Pradella S; Treballi F; Bicci E
Diagnostics (Basel); 2023 Aug; 13(15):. PubMed ID: 37568954
[TBL] [Abstract][Full Text] [Related]
6. Whole‑body MRI for metastatic workup in patients diagnosed with cancer.
Rashid RJ; Tahir SH; Kakamad FH; Omar SS; Salih AM; Ahmed SF; Abdalla SH; Naqar S; Salih RQ; Kakamad SH; Mohammed KK; Mustafa SM; Hassan MN; Mohammed SH
Mol Clin Oncol; 2023 Apr; 18(4):33. PubMed ID: 36925744
[TBL] [Abstract][Full Text] [Related]
7. Differentiating peripheral cholangiocarcinoma in stages T1N0M0 and T2N0M0 from hepatic hypovascular nodules using dynamic contrast-enhanced MRI.
Li S; Qian H; Peng Y; Jia H; Lin G
Sci Rep; 2017 Aug; 7(1):8084. PubMed ID: 28808285
[TBL] [Abstract][Full Text] [Related]
8. 18 F-FDG PET/MR imaging in patients with suspected liver lesions: Value of liver-specific contrast agent Gadobenate dimeglumine.
Kirchner J; Sawicki LM; Deuschl C; Grüneisen J; Beiderwellen K; Lauenstein TC; Herrmann K; Forsting M; Heusch P; Umutlu L
PLoS One; 2017; 12(7):e0180349. PubMed ID: 28683109
[TBL] [Abstract][Full Text] [Related]
9. [Optimized detection and characterization of liver metastases : The role of current MRI contrast agents].
Weinrich JM; Well L; Bannas P
Radiologe; 2017 May; 57(5):373-381. PubMed ID: 28204853
[TBL] [Abstract][Full Text] [Related]
10. Hypo-Vascular Liver Metastases Treated with Transarterial chemoembolization: Assessment of Early Response by Volumetric Contrast-Enhanced and Diffusion-Weighted Magnetic Resonance Imaging.
Sobhani F; Xu C; Murano E; Pan L; Rastegar N; Kamel IR
Transl Oncol; 2016 Aug; 9(4):287-94. PubMed ID: 27567951
[TBL] [Abstract][Full Text] [Related]
11. Improved Visibility of Metastatic Disease in the Liver During Intra-Arterial Therapy Using Delayed Arterial Phase Cone-Beam CT.
Schernthaner RE; Haroun RR; Duran R; Lee H; Sahu S; Sohn JH; Chapiro J; Zhao Y; Gorodetski B; Fleckenstein F; Smolka S; Radaelli A; van der Bom IM; Lin M; Geschwind JF
Cardiovasc Intervent Radiol; 2016 Oct; 39(10):1429-37. PubMed ID: 27380872
[TBL] [Abstract][Full Text] [Related]
12. Combined gadoxetic acid and gadofosveset enhanced liver MRI for detection and characterization of liver metastases.
Bannas P; Bookwalter CA; Ziemlewicz T; Motosugi U; Munoz Del Rio A; Potretzke TA; Nagle SK; Reeder SB
Eur Radiol; 2017 Jan; 27(1):32-40. PubMed ID: 27137648
[TBL] [Abstract][Full Text] [Related]
13. Morphologic and Functional Imaging of Non-Colorectal Liver Metastases.
Heusch P; Antoch G
Viszeralmedizin; 2015 Dec; 31(6):387-92. PubMed ID: 26889141
[TBL] [Abstract][Full Text] [Related]
14. [Modern imaging of liver metastases].
Breitenseher J; Pones M; Wengert G; Ba-Ssalamah A
Radiologe; 2015 Jan; 55(1):36-42. PubMed ID: 25609579
[TBL] [Abstract][Full Text] [Related]
15. Focal liver lesions detection and characterization: The advantages of gadoxetic acid-enhanced liver MRI.
Palmucci S
World J Hepatol; 2014 Jul; 6(7):477-85. PubMed ID: 25067999
[TBL] [Abstract][Full Text] [Related]
16. Functional imaging biomarkers for assessing response to treatment in liver and lung metastases.
Bernardin L; O'Flynn EA; Desouza NM
Cancer Imaging; 2013 Dec; 13(4):482-94. PubMed ID: 24334562
[TBL] [Abstract][Full Text] [Related]
17. Is hepatotropic contrast enhanced MR a more effective method in differential diagnosis of hemangioma than multi-phase CT and unenhanced MR?
Szurowska E; Nowicki T; Izycka-Swieszewska E; Wypych J; Drobinska-Jurowiecka A; Markiet K; Szarmach A; Studniarek M
BMC Gastroenterol; 2011 Apr; 11():43. PubMed ID: 21504593
[TBL] [Abstract][Full Text] [Related]
18. Magnetic resonance imaging of the liver: New imaging strategies for evaluating focal liver lesions.
Coenegrachts K
World J Radiol; 2009 Dec; 1(1):72-85. PubMed ID: 21160723
[TBL] [Abstract][Full Text] [Related]
19. Imaging of liver metastases: MRI.
Namasivayam S; Martin DR; Saini S
Cancer Imaging; 2007; 7(1):2-9. PubMed ID: 17293303
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
